Revealing the true value of new cancer drugs to payersMarc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new Share XRevealing the true value of new cancer drugs to payershttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/pharmerit-cancer-drug-value-payers/
